Polynucleotides for Skin: The 2026 Evidence Review

What are polynucleotides, exactly?

Polynucleotides (PN) and polydeoxyribonucleotides (PDRN) are DNA-based fragments, typically derived from salmon or trout sperm. When injected into skin, they trigger fibroblasts — the cells responsible for making collagen — to increase collagen synthesis. This is a different mechanism from dermal fillers, which physically add volume, or growth factors, which signal cellular activity.

The injectable form is what's making noise in aesthetics clinics in 2026. It's different from topical serums or oral supplements claiming the same thing. Injected polynucleotides reach the dermis directly, where they work on the cells that actually build skin structure.

Polynucleotides vs. dermal fillers: the honest difference

Here's the critical distinction. Dermal fillers (like hyaluronic acid or calcium hydroxylapatite) work by adding physical volume to smooth lines. You get immediate results. But the filler breaks down over time, and you need repeat treatments.

Polynucleotides work differently. They stimulate your own skin to make more collagen. The results are slower — typically visible over 4–8 weeks as your skin rebuilds itself. But because they're stimulating collagen production, not adding a substance, the results can last longer. Filler is instant gratification. Polynucleotides are slower — they're building something, not filling a gap.

What the clinical evidence actually shows

A 2025 systematic review analysed 360 studies covering 750 participants. The good news: the body of evidence suggests polynucleotides improve skin elasticity, diminish wrinkles, reduce acne scars, and accelerate wound healing. Adverse effects are low — mostly temporary redness, swelling, or bruising.

The catch: study quality is inconsistent. Dosing varies widely. Delivery methods differ (intradermal, subdermal, microneedling-assisted). Outcome measurements aren't standardised. One trial measures elasticity by texture analysis. Another uses patient satisfaction. That makes it difficult to say definitively "this dose produces these results" because there's no gold standard.

Who benefits most from polynucleotides

• ✓ Women with early-to-moderate fine lines and loss of skin elasticity (ages 30–50)
• ✓ People with textural concerns (roughness, uneven tone) but not significant volume loss
• ✓ Those with acne scars that are shallow to moderate (not deep pitted scars)
• ✗ Women with significant volume loss may need filler in addition; polynucleotides alone won't restore cheekbone height

The honest gaps and next steps

Long-term safety data beyond 12 months is sparse. We don't yet know whether repeated polynucleotide treatments over 5 years are safe or whether there's an optimal treatment frequency. The sourcing and standardisation of PDRN products varies by manufacturer, meaning you're not getting a uniform product across different brands.

This isn't a reason to avoid polynucleotides. It's a reason to be selective about your provider — someone who uses a well-researched brand with published safety data and can explain the specific protocol they're using.